S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.33
+1.65
+9.89%
AUTL · Autolus Therapeutics plc American Depositary Share
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Autolus Therapeutics PLC (AUTL)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.61
-0.04
(-2.42%)
● At close: October 21 at 4:00:00 PM EDT
$1.63
+0.01
(+0.62%)
Overnight:
12:08:33 AM EDT
DAY'S RANGE
$1.61
$1.61
$1.68
52-WEEK RANGE
$1.61
$1.18
$2.58
What's happening
- AUTL is down 2.42% today, trading at $1.61. — Live quote
- Volume today (148,512) is well below its 3-month average of 1,856,160. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.15 actual vs. $-0.22 estimated (+31.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AUTL
-20.10%
vs S&P 500
-32.50%
1-YEAR RETURN
AUTL
-1.85%
vs S&P 500
-17.22%
6-MONTH RETURN
AUTL
+6.71%
3-MONTH RETURN
AUTL
+13.57%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.15
Est. $-0.22
BEAT +31.8%
2026-04-26 (Q1 2026)
$-0.27
Est. $-0.26
MISS -2.9%
2026-01-26 (Q4 2025)
$-0.34
Est. $-0.27
MISS -25.2%
2025-10-26 (Q3 2025)
$-0.30
Est. $-0.23
MISS -30.3%
Valuation Measures & Ratios
Enterprise Value4$541.8M
Forward P/E5—
PEG Ratio6-0.07
Price / Sales (TTM1)3.76
Price / Book75.69
EV4 / Revenue4.62
EV4 / EBITDA—
Profit Margin-238.66%
Operating Margin-210.78%
Return on Equity (ROE8)-178.66%
Return on Assets (ROA9)-49.34%
Avg Volume (3M)1,856,160
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $417.2M | $365.9M | $428.6M | $609.6M | $416.9M |
| P/E | -1.75 | -1.36 | -1.53 | -2.36 | -1.58 |
| Price/Sales | 3.66 | 4.73 | 8.39 | 20.38 | — |
| Price/Book | 5.57 | 3.36 | 1.61 | 1.76 | 1.12 |
| EV/Revenue | 2.16 | 3.04 | 6.70 | 16.24 | — |
| EV/EBITDA | -1.08 | -0.94 | -1.33 | — | — |
| ROE | -317.67% | -246.99% | -105.21% | -74.59% | -70.93% |
| ROA | -48.20% | -51.00% | -42.19% | -35.85% | -35.27% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short8,400,156
Change from Prior Settlement+0.89%
% of Float—
Days to Cover (Short Ratio)5.66
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 118.4% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-03; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -238.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -1.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AUTL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.7M | $26.2M | $21.2M | $20.9M | $9.0M | $0 | $0 | — |
| Operating income | -$43.8M | -$59.5M | -$71.6M | -$61.2M | -$65.2M | -$67.9M | -$58.9M | -$38.8M |
| Net income | -$39.1M | -$71.6M | -$79.1M | -$47.9M | -$70.2M | -$82.1M | -$58.3M | -$52.7M |
| EPS (diluted) | $-0.15 | $-0.27 | $-0.30 | $-0.18 | $-0.26 | $-0.31 | $-0.22 | $-0.24 |
| EPS (basic) | $-0.15 | $-0.27 | $-0.30 | $-0.18 | $-0.26 | $-0.31 | $-0.22 | $-0.24 |
| Operating margin | -$96 | -$227 | -$338 | -$293 | -$726 | — | — | — |
| Net margin | -$86 | -$273 | -$373 | -$229 | -$781 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $493.2M | $527.1M | $589.1M | $661.9M | $721.0M | $746.3M | $782.7M | $827.5M |
| Total liabilities | $418.4M | $418.2M | $410.9M | $396.5M | $374.5M | $375.2M | $355.4M | $350.5M |
| Stockholders' equity | $74.8M | $108.8M | $178.1M | $265.5M | $346.5M | $371.1M | $427.3M | $477.0M |
| Total current assets | $336.1M | $368.8M | $435.9M | $514.6M | $574.2M | $615.8M | $660.9M | $718.1M |
| Total current liabilities | $68.8M | $63.6M | $73.4M | $83.1M | $68.2M | $66.6M | $60.7M | $52.5M |
| Cash & equivalents | $171.4M | $130.9M | $104.1M | $86.1M | $123.8M | $95.8M | $227.4M | $657.1M |
| Accounts receivable | $44.4M | $27.7M | $24.0M | — | — | — | $15.0K | $0 |
| Inventory | $33.4M | $33.2M | $33.2M | $27.7M | $23.9M | $14.6M | $4.1M | — |
| Other current assets | — | — | $0 | — | $0 | $1.6M | $1.6M | — |
| Property, plant & equipment | $60.5M | $61.9M | $63.6M | $66.9M | $66.5M | $58.0M | $49.6M | $44.3M |
| Intangible assets | $18.5M | $19.0M | $19.8M | $20.3M | $12.9M | $12.5M | $12.4M | — |
| Accounts payable | $1.4M | $1.9M | $3.1M | $11.0M | $5.4M | $4.5M | $2.0M | $1.4M |
| Accrued liabilities | $48.7M | $46.8M | $55.8M | $52.3M | $51.4M | $49.7M | $52.3M | $47.5M |
| Deferred revenue (current) | — | — | — | — | — | $4.8M | $3.5M | — |
| Other current liabilities | $2.5M | $2.6M | $2.0M | $2.4M | $2.1M | $2.4M | $479.0K | $403.0K |
| Other non-current liabilities | $474.0K | $477.0K | $477.0K | $472.0K | $477.0K | $444.0K | $426.0K | $447.0K |
| Retained earnings | -$1.50B | -$1.46B | -$1.39B | -$1.30B | -$1.22B | -$1.17B | -$1.10B | -$1.07B |
| Accumulated other comprehensive income (loss) | -$6.1M | -$6.6M | -$5.4M | -$4.9M | $862.0K | -$18.1M | -$29.2M | -$898.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.1M | -$65.3M | -$67.3M | -$67.9M | -$72.8M | -$75.6M | -$37.9M | -$76.7M |
| Investing cash flow | $67.9M | $96.2M | $86.5M | $35.5M | $95.9M | -$59.5M | -$383.6M | -$9.6M |
| Financing cash flow | -$2.1M | -$2.1M | -$1.8M | -$1.8M | -$768.0K | $0 | $30.0M | $185.0K |
| Free cash flow | -$26.0M | -$68.0M | -$66.4M | -$72.3M | -$80.1M | -$83.8M | -$49.0M | -$86.3M |
| Capital expenditures | $913.0K | $2.7M | -$885.0K | $4.4M | $7.3M | $8.2M | $11.1M | $9.6M |
| Depreciation & amortization | $2.2M | $2.2M | $2.1M | $2.1M | $2.1M | $2.0M | $1.9M | $1.9M |
| Deferred income taxes | — | — | -$631.0K | — | — | — | -$175.0K | — |
| Change in accounts receivable | $16.7M | $3.6M | -$8.6M | $6.0M | $12.4M | $14.3M | $0 | $0 |
| Change in inventory | $1.2M | $2.5M | $10.1M | $8.6M | $11.4M | $10.1M | $4.2M | $0 |
| Change in accounts payable | -$667.0K | -$1.2M | -$7.5M | $5.4M | $1.5M | $1.9M | $331.0K | $276.0K |
| Purchases of investments | $0 | $14.7M | $40.4M | $82.9M | $48.0M | $71.3M | $359.7M | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | — | — | — |
| Operating income | -$270.5M | -$241.4M | -$179.7M | -$143.4M | -$141.1M |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M | -$142.1M |
| EPS (diluted) | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 |
| EPS (basic) | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 |
| Operating margin | -$359 | -$2.4K | — | — | — |
| Net margin | -$381 | -$2.2K | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|
| Total assets | $589.1M | $782.7M | $375.4M | $406.1M | $451.0M |
| Total liabilities | $410.9M | $355.4M | $263.9M | $225.6M | $221.7M |
| Stockholders' equity | $178.1M | $427.3M | $111.5M | $180.5M | $229.3M |
| Total current assets | $435.9M | $660.9M | $275.3M | $308.4M | $355.4M |
| Total current liabilities | $73.4M | $60.7M | $44.7M | $37.5M | $41.1M |
| Cash & equivalents | $104.1M | $227.4M | $239.6M | $256.4M | $307.5M |
| Accounts receivable | $24.0M | $15.0K | $109.0K | — | — |
| Inventory | $33.2M | $4.1M | $0 | — | — |
| Other current assets | $0 | $1.6M | $0 | — | — |
| Property, plant & equipment | $63.6M | $49.6M | $34.9M | $34.6M | $36.9M |
| Intangible assets | $19.8M | $12.4M | $0 | — | — |
| Accounts payable | $3.1M | $2.0M | $103.0K | $661.0K | $3.9M |
| Accrued liabilities | $55.8M | $52.3M | $39.6M | $31.4M | $31.0M |
| Deferred revenue (current) | — | $3.5M | $0 | — | — |
| Other current liabilities | $2.0M | $479.0K | $533.0K | — | — |
| Other non-current liabilities | $477.0K | $426.0K | $357.0K | $295.0K | $122.0K |
| Retained earnings | -$1.39B | -$1.10B | -$878.6M | -$801.4M | -$755.5M |
| Accumulated other comprehensive income (loss) | -$5.4M | -$29.2M | -$29.0M | -$33.8M | -$28.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$283.6M | -$206.3M | -$145.6M | -$112.3M | -$117.9M |
| Investing cash flow | $158.5M | -$394.6M | -$11.0M | -$10.8M | -$8.9M |
| Financing cash flow | -$4.3M | $589.6M | -$883.0K | $223.6M | $284.1M |
| Free cash flow | -$302.6M | -$228.3M | -$156.6M | -$123.1M | -$126.7M |
| Capital expenditures | $19.0M | $22.1M | $11.0M | $10.8M | $8.9M |
| Depreciation & amortization | $8.3M | $7.6M | $6.6M | $7.4M | $8.5M |
| Deferred income taxes | -$631.0K | -$175.0K | -$987.0K | -$213.0K | -$110.0K |
| Change in accounts receivable | $24.2M | $0 | — | — | — |
| Change in inventory | $40.2M | $4.2M | $0 | — | — |
| Change in accounts payable | $1.3M | $1.6M | -$509.0K | $22.0K | -$1.8M |
| Purchases of investments | $242.6M | $359.7M | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AUTL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 10 most recent filings · covers 2026-09-01 to 2026-09-02
Recent transactions
- Insiders have net sold 6,713 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Piccina Cintia (U.S. CCO & Country Gen Manager) — Open market sale of 6,713 shares on 2026-09-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)6,713 sh(1 txns)
Net Shares-6,713
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Piccina Cintia | U.S. CCO & Country Gen Manager | Open market sale | 2026-09-02 | 6,713 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-02 | Piccina Cintia | U.S. CCO & Country Gen Manager | Open market sale | 6,713 | $2.34 |
| 2026-09-01 | Piccina Cintia | U.S. CCO & Country Gen Manager | Option exercise | 20,000 | $2.35 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:01 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-07-30 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
Recent news
Headlines about AUTL (Autolus Therapeutics plc American Depositary Share). Links open the publisher — we don’t host full articles.
-
Which of Senti Biosciences (NASDAQ:SNTI), Autolus Therapeutics (NASDAQ:AUTL), Scinai Immunotherapeutics (NASDAQ:SCNI), Estrella Immunopharma (NASDAQ:ESLA) or Shuttle Pharmaceuticals (NASDAQ:SHPH) Is the Weakest Biotech o
kalkine.ca · 2026-10-16 -
Why Is Autolus Therapeutics (NASDAQ:AUTL) Down 10.92% Pre-Market, and Is More Selling Ahead?
kalkine.ca · 2026-10-16 -
Which of Concorde International Group (NASDAQ:CIGL), Autolus Therapeutics (NASDAQ:AUTL), Arcadia Biosciences (NASDAQ:RKDA), MasterBeef Group (NASDAQ:MB) or TNL Mediagene (NASDAQ:TNMG) Fell 10% to 11% in Pre-Market?
kalkine.ca · 2026-10-16 -
Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst Predictions
Simply Wall Street · 2026-10-16 -
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Yahoo Finance · 2026-10-05 -
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Yahoo Finance · 2026-10-05 -
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
Yahoo Finance · 2026-09-12 -
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Yahoo Finance · 2026-09-09
No headlines in this category right now — try “All”.